Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease

Rhea-AI Summary

Premier, Inc. (PINC) has partnered with AstraZeneca in Uncover CKD - Care Collective to improve diagnosis and care for chronic kidney disease (CKD). The initiative aims to address the high number of undiagnosed CKD patients in the U.S. through real-world data and AI-powered technologies. With over 37 million adults in the U.S. having CKD, the partnership seeks to lower healthcare costs and improve patient outcomes by leveraging Premier's PINC AI™ technology and services platform.

Positive

• Partnership with AstraZeneca for Uncover CKD - Care Collective to improve CKD diagnosis and care.

• Utilization of real-world data and AI-powered technologies to identify undiagnosed CKD patients.

• Focus on lowering healthcare costs and improving patient outcomes in the U.S.

• Innovative approaches to driving optimization of guideline-directed medical therapy for patients.

Negative

• High prevalence of undiagnosed CKD patients in the U.S.

• Economic burden of $53 billion in Medicare expenditures for end-stage renal disease patients.

• Cost of preventable hospitalizations for CKD patients amounting to $79 million.

• Challenges in managing CKD and limiting downstream costs associated with severe disease stages.

Collaboration between Premier, AstraZeneca and leading health systems will leverage real-world data, artificial intelligence-powered technologies and scalable solutions to help improve the health of patients and lower the cost of care.

CHARLOTTE, N.C.--(BUSINESS WIRE)-- Premier, Inc. (NASDAQ: PINC) is excited to announce a strategic partnership with AstraZeneca called Uncover CKD - Care Collective aiming to identify patients with undiagnosed clinical chronic kidney disease (CKD); raise awareness of undiagnosed CKD among healthcare providers; and inform U.S. health systems that want to improve or develop and implement their strategies for CKD diagnosis, treatment and management.

In the U.S., more than 37 million adults have CKD, and the prevalence is rising. Of these adult patients, 90 percent do not know they have CKD. Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019. Among CKD patients, the cost of preventable hospitalizations is $79 million.

Through collaborative initiatives and scalable solutions from across the Premier enterprise, including its PINC AI™ technology and services platform, the Uncover CKD - Care Collective is addressing undiagnosed and rising CKD and the resulting economic burden to the U.S. healthcare system. The partnership with AstraZeneca demonstrates a commitment to implement and learn about innovative approaches to driving optimization of guideline-directed medical therapy for patients.

“We’re thrilled to be working with AstraZeneca and Premier member health systems to help solve the myriad challenges CKD presents to patients and our healthcare system,” said Leigh Anderson, Chief Operating Officer, Premier. “The Uncover CKD - Care Collective initiative highlights the impact collaborative partnerships across life sciences organizations and health systems – coupled with actionable real-world data (RWD), artificial intelligence (AI)-powered clinical and operational solutions, and best-practice consulting and collaboratives – can have in improving the care and cost of treating chronic diseases. As our collective work moves the needle on the rate of CKD diagnosis, those patients previously undiagnosed can begin to be treated and their conditions managed, limiting down-the-line costs associated with more severe disease stages.”

The Uncover CKD - Care Collective is poised to make significant strides in improving CKD diagnosis and advancing patient care through the utilization of:

• PINC AI™ Applied Sciences (PAS) RWD leveraging the robust PINC AI™ Healthcare Database, laboratory data and technology to identify high-volume areas of unidentified, at-risk patients; screen undiagnosed CKD patients, estimate prevalence and report hospital-specific patient counts; and describe patient characteristics and the clinical and economic outcomes of undiagnosed CKD. This discovery phase work has been completed and findings disseminated to characterize the burden of CKD across the health systems, prioritize and focus hospital-level initiatives, and commit to sustainable organizational change.
• PAS Improvement Science’s Health System Awareness Package, including provider and patient education, provider resources and workflow processes as well as support for participating health systems through provider engagement – all created to be scaled broadly across Premier’s health system network.
• PINC AI™ Stanson AI-powered technology, including clinical decision support and real-time alerts integrated into the provider workflow, to help strategically modify provider behavior to improve CKD screening, diagnosis and care quality.
• PINC AI™ Advisory Services to actively engage physicians, foster mutual accountability and drive clinical transformation and quality improvement efforts around CKD diagnosis, treatment and management throughout the health systems.
• Premier Pharmacy and Group Purchasing Organization resources to optimize medication management protocols and streamline operational processes for enhanced efficiency and positive patient outcomes.
• PINC AI™ Population Health Management Collaborative, including member Accountable Care Organizations (ACOs) and those on the transformation to value-based care, to facilitate idea exchange and best practice sharing.
• Health system collaboration to share project outcomes, publish a white paper, develop a poster presentation for the National Kidney Foundation and present findings at Premier’s 2024 Breakthroughs Conference & Exhibition.

“Through commitment to AstraZeneca’s medical missions of putting patients first and following the science, the Uncover CKD program is applying RWD to create urgency to diagnose and treat patients with CKD. With this innovative partnership we are leveraging relationships with health systems to improve care for 2.8 million patients identified to benefit from earlier CKD diagnosis and treatment,” said Rachele Berria, Vice President and Medical Head, US BioPharmaceuticals, AstraZeneca.

Health System Selection Criteria

In the selection of target health systems for the Uncover CKD - Care Collective, the project team considered disease burden, patient composition (e.g., age, sex, race, ethnicity), payer composition (e.g., Medicaid, Medicare, uninsured), hospital region (geographic diversity), urbanicity of served population, teaching status and hospital size. Priority was given to health systems serving many socially disadvantaged patients (i.e., health equity). For patient outreach efforts, the project team provided screening algorithms to the target sites so that they can identify socially disadvantaged patients with undiagnosed CKD for targeted outreach.

Hospitals and health systems in the U.S. can request access to the online PINC AI™ Community “Chronic Kidney Disease (CKD): Diagnosis and Mgmt.” to obtain outreach materials that have been developed as part of the Uncover CKD Project such as educational resources and tools for patients and healthcare professionals. Premier will work with respective hospitals or health systems to provide relevant resources, based on needs. For example, these resources could include the CKD Care Journey Roadmap, CKD Health Equity Primer, clinical decision support documentation (algorithms) and other digitized resources.

About Premier, Inc.

Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and health systems and approximately 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

About the PINC AI™ Platform

PINC AI^™ is the technology and services platform of Premier, Inc. (NASDAQ: PINC). With more than 20 years’ worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 2.7 billion hospital outpatient and clinic encounters and 177 million physician office visits, the PINC AI^™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI^™ incorporates the 100 Top Hospitals ^® Program that inspires hospital and health system leaders to pursue higher performance and deliver added value to their patients and communities. PINC AI^™ offerings rely on advanced analytics to identify improvement opportunities; support award-winning Strategic Collaboratives for value-based care, maternal and infant health, workforce innovation, and health equity; and consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI^™ platform is also the data engine powering Premier’s newest brands – Remitra^® and Contigo Health^®. With a leading network of provider organizations, the PINC AI^™ platform accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. PINC AI^™ offerings and capabilities can be followed on X and LinkedIn.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts, including but not limited to those relating to Premier's ability to advance its long-term strategies and develop innovations for, transform, and improve healthcare, and the intended or expected performance or utility of Premier's products and services, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements to be materially different from historical results or from any future performance or achievements expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC, which are also made available on Premier’s website at investors.premierinc.com. Forward-looking statements speak only as of the date they are made, and Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508239890/en/

public_relations@premierinc.com

Source: Premier, Inc.

FAQ

What is the purpose of the Uncover CKD - Care Collective initiative?

The initiative aims to improve diagnosis and care for chronic kidney disease (CKD) through real-world data and AI-powered technologies.

How many adults in the U.S. have CKD?

More than 37 million adults in the U.S. have CKD.

What is the economic burden of CKD in terms of Medicare expenditures?

Total inflation-adjusted Medicare expenditures for end-stage renal disease patients increased to $53 billion in 2019.

What are the challenges associated with undiagnosed CKD patients?

90 percent of adult patients with CKD do not know they have the disease, leading to challenges in managing and treating CKD.

How does Premier plan to address the economic burden of CKD?

Premier aims to leverage its PINC AI™ technology and services platform to identify undiagnosed CKD patients and lower healthcare costs.

What resources are available for hospitals and health systems interested in the Uncover CKD initiative?

Hospitals and health systems in the U.S. can request access to the online PINC AI™ Community for outreach materials and educational resources related to CKD diagnosis and management.